Last reviewed · How we verify

Cyclosporine 0.010% eye drops

Allergan · Phase 2 active Small molecule

Cyclosporine 0.010% eye drops is a Calcineurin inhibitor Small molecule drug developed by Allergan. It is currently in Phase 2 development for Prevention of organ rejection in transplant patients.

Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation.

Cyclosporine 0.010% eye drops, developed by Allergan, is a novel ophthalmic solution in Phase 3 for treating atopic keratoconjunctivitis. It has completed a Phase 2 trial in post-LASIK patients, showing promise in reducing inflammation and improving ocular surface health.

At a glance

Generic nameCyclosporine 0.010% eye drops
SponsorAllergan
Drug classCalcineurin inhibitor
TargetCalcineurin
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 2

Mechanism of action

By inhibiting calcineurin, cyclosporine prevents the transcription of interleukin-2 (IL-2), a key cytokine involved in T-cell proliferation. This results in a decrease in T-cell activation and subsequent immune response. This mechanism is particularly useful in preventing organ rejection in transplant patients.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cyclosporine 0.010% eye drops

What is Cyclosporine 0.010% eye drops?

Cyclosporine 0.010% eye drops is a Calcineurin inhibitor drug developed by Allergan, indicated for Prevention of organ rejection in transplant patients.

How does Cyclosporine 0.010% eye drops work?

Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation.

What is Cyclosporine 0.010% eye drops used for?

Cyclosporine 0.010% eye drops is indicated for Prevention of organ rejection in transplant patients.

Who makes Cyclosporine 0.010% eye drops?

Cyclosporine 0.010% eye drops is developed by Allergan (see full Allergan pipeline at /company/allergan).

What drug class is Cyclosporine 0.010% eye drops in?

Cyclosporine 0.010% eye drops belongs to the Calcineurin inhibitor class. See all Calcineurin inhibitor drugs at /class/calcineurin-inhibitor.

What development phase is Cyclosporine 0.010% eye drops in?

Cyclosporine 0.010% eye drops is in Phase 2.

What are the side effects of Cyclosporine 0.010% eye drops?

Common side effects of Cyclosporine 0.010% eye drops include Hypertension, Nephrotoxicity, Diabetes mellitus, Hirsutism, Gingival hyperplasia.

What does Cyclosporine 0.010% eye drops target?

Cyclosporine 0.010% eye drops targets Calcineurin and is a Calcineurin inhibitor.

Related